Aktis Oncology, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
During the three months ended June 30, 2026, the following directors and/or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” in each case as defined in Item 408 of Regulation S-K.
| Character of Trading Arrangement | |||||||
| Name and Title | Action Taken | Date of Action | Rule 10b5-1* | Non-Rule 10b5-1 | Nature of Trading | Aggregate Number of Securities (1) | Duration of Trading Arrangement |
|---|---|---|---|---|---|---|---|
| Akos Czibere, Chief Medical Officer | Adopted | June 24, 2026 | X | Sale | 50,000 shares | 9/23/2026 - 6/30/2027 | |
| Shulamit Ron-Bigger, Chief Operating Officer | Adopted | June 25, 2026 (2) | X | Sale | 50,000 shares | 9/24/2026 - 6/30/2027 | |
- Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(1) This amount represents the maximum total shares that could be sold under the plan.
(2) On July 7, 2026, Ms. Ron-Bigger terminated her trading plan prior to any shares of common stock being sold pursuant to the trading plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.